bs-4888R [Primary Antibody]
PPAR Gamma (ser273) Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: PPAR Gamma ser273

Modification Site: ser273

Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 5468

Swiss Prot: P37231

Source: KLH conjugated synthetic phosphopeptide derived from human PPAR Gamma around the phosphorylation site of ser273

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.

Background:

Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
IHC-P(1:200-400)
IHC-F(1:100-500)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)

Predicted Molecular Weight: 57


Cross Reactive Species: Human

Predicted Cross Reactive Species: Mouse
Rat
Cow
Sheep
Chicken
Rabbit

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Kolli, Vipula, et al. "Partial Agonist, Telmisartan, Maintains PPARγ Serine 112 Phosphorylation, and Does Not Affect Osteoblast Differentiation and Bone Mass." PLOS ONE 9.5 (2014): e96323.Read more>>
  • Pandurangan, Muthuraman, Jeongeun Park, and Eunjung Kim. "Aspartame downregulates 3T3-L1 differentiation." In Vitro Cellular & Developmental Biology-Animal (2014): 1-7.Read more>>
  • Liu, Chang, et al. "Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis." Scientific Reports 5 (2015).Read more>>
  • Agrawal, S., et al. "Pioglitazone Enhances the Beneficial Effects of Glucocorticoids in Experimental Nephrotic Syndrome." Scientific Reports 6 (2016): 24392.Read more>>
  • Stechschulte, Lance A., et al. "Protein Phosphatase PP5 Controls Bone Mass and the Negative Effects of Rosiglitazone on Bone through Reciprocal Regulation of PPARγ and RUNX2." Journal of Biological Chemistry (2016).Read more>>
  • Maganti, Aarthi V., et al. "Peroxisome Proliferator-Activated Receptor-γ Activation Augments the β Cell Unfolded Protein Response and Rescues Early Glycemic Deterioration and β Cell Death in Non-Obese Diabetic Mice."Journal of Biological Chemistry (2016): jbc-M116.Read more>>
  • Alla, Joshua Abd, et al. "Inhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice." Journal of Biological Chemistry 291.6 (2016): 2583-2600.Read more>>
  • Liu, Lei, et al. "Dihydromyricetin delays the onset of hyperglycemia and ameliorates insulin resistance without excessive weight gain in Zucker diabetic fatty rats." Molecular and Cellular Endocrinology (2016).Read more>>
  • Sarr, Ousseynou, et al. "Low birth weight male guinea pig offspring display increased visceral adiposity in early adulthood." PloS one 9.6 (2014): e98433.Read more>>
  • Yuan, Hai-Feng, et al. "Expression of p-PPARγ in the aging thoracic aorta of spontaneously hypertensive rat and inhibitory effect of rosiglitazone." Asian Pacific Journal of Tropical Biomedicine 4.12 (2014): 977-981.Read more>>
  • Liu, Lei, et al. "Dihydromyricetin enhances glucose uptake by inhibition of MEK/ERK pathway and consequent down‐regulation of phosphorylation of PPARγ in 3T3‐L1 cells." Journal of Cellular and Molecular Medicine (2017).Read more>>
  • Liu Y et al. Isolation and characterization of ovine monocyte-derived macrophages from peripheral blood.(2018)Vet Immunol Immunopathol. Nov;205:83-92. Read more>>
  • Hou et al. CMHX008, a PPARγ partial agonist, enhances insulin sensitivity with minor influences on bone loss. (2018) Genes.Dis. 5:290-299Read more>>
  • Li B et al. Resistin up-regulates LPL expression through the PPARγ-dependent PI3K/AKT signaling pathway impacting lipid accumulation in RAW264. 7 macrophages.Cytokine. 2019 Jul;119:168-174.Read more>>
  • Zhang C et al. Osteoprotegerin Promotes Liver Steatosis by Targeting the ERK-PPARγ-CD36 Pathway. Diabetes. 2019 Jul 10. pii: db181055. Read more>>
  • Huan Y et al. A novel specific PPARγ modulator YR4‐42 ameliorates hyperglycemia and dyslipidemia and hepatic steatosis in diet‐induced obese mice. Diabetes Obes Metab. 2019 Jul 31.Read more>>
  • Stephanie Kimet al. Triphenyl phosphate is a selective PPAR modulator that does not induce brite adipogenesis in vitro and in vivo. Arch Toxicol. 2020 Sep;94(9):3087-3103.Read more>>
  • Ye Zhanget al. Thymopentin improves the survival of septic mice by promoting the production of 15\deoxy\prostaglandin J2 and activating the PPAR signaling pathway. FASEB J. 2020 Sep;34(9):11772-11785.Read more>>
  • Yingying Tian. et al. Exogenous natural EPA-enriched phosphatidylcholine and phosphatidylethanolamine ameliorate lipid accumulation and insulin resistance via activation of PPAR/ in mice. Food Funct. 2020 Sep;11(9):8248-8258Read more>>
  • Qiankun Quan. et al. Ginsenoside Rg1 reduces β?amyloid levels by inhibiting CDΚ5?induced PPARγ phosphorylation in a neuron model of Alzheimer's disease. Mol Med Rep. 2020 Oct;22(4):3277-3288Read more>>
  • Pengyu Hong. et al. Therapeutic potential of small extracellular vesicles derived from lipoma tissue in adipose tissue regenerationan in vitro and in vivo study. Stem Cell Res Ther. 2021 Dec;12(1):1-13Read more>>
  • Lei Ma. et al. Identification of the anti-fungal drug fenticonazole nitrate as a novel PPAR-modulating ligand with good therapeutic index: Structure-based screening and biological validation. Pharmacol Res. 2021 Nov;173:10586Read more>>
  • Dan Wu. et al. A Novel Peroxisome Proliferator-Activated Receptor Gamma Ligand Improves Insulin Sensitivity and Promotes Browning of White Adipose Tissue in Obese Mice. Mol Metab. 2021 Oct;:101363Read more>>
  • Wang, Xu. et al. Modulatory effect of euxanthone in liver cancer-bearing obese mice: crosstalk between PPAR and TIMP3 signalling axes. 3 Biotech. 2021 Nov;11(11):1-7Read more>>
  • Kiyoko Maruyama. et al. Indomethacin, a non-steroidal anti-inflammatory drug, induces skin dryness via PPAR in mice. 2021 Oct 3Read more>>
  • Shihe Zhang. et al. Astragalus polysaccharide regulates brown adipocytes differentiation by miR-6911 targeting Prdm16. 2021 Nov 05Read more>>
  • Claire Bryant. et al. Selective Modulator of Nuclear Receptor PPAR_ with Reduced Adipogenic Potential Ameliorates Experimental Nephrotic Syndrome. Iscience. 2022 Feb;:104001Read more>>
  • Aozora Nagaoka. et al. Sorghum (Sorghum bicolor) Extract-Induced Adipogenesis Is Independent of PPAR_ Ser273 Phosphorylation in 3T3-L1 Adipocytes. BIOL PHARM BULL. 2022 May;45(5):659-663Read more>>
  • Yu Wang. et al. An integrated study of Shenling Baizhu San against hyperuricemia: Efficacy evaluation, core target identification and active component discovery. J ETHNOPHARMACOL. 2022 Sep;295:11545Read more>>
  • Li, Lu. et al. Luteolin alleviates inflammation and autophagy of hippocampus induced by cerebral ischemia/reperfusion by activating PPAR gamma in rats. BMC Complementary Medicine and Therapies. 2022 Dec;22(1):1-13Read more>>
  • Yaru Guo. et al. Pioglitazone Attenuates Ischemic Stroke Aggravation By Blocking PPAR Reduction and Inhibiting Chronic Inflammation in Diabetic Mice. EUR J NEUROSCI. 2022 AugRead more>>
  • Fangyuan Chen. et al. Identification of a novel PPAR modulator with good anti-diabetic therapeutic index via structure-based screening, optimization and biological validation. BIOMED PHARMACOTHER. 2022 Oct;154:113653Read more>>
  • Junyuan Tang. et al. Structure-based screening and biological validation of the anti-thrombotic drug-dicoumarol as a novel and potent PPAR-modulating ligand. BIOORG CHEM. 2022 Oct;:106191Read more>>
  • Yang, Nanfei. et al. Blockage of PPAR T166 phosphorylation enhances the inducibility of beige adipocytes and improves metabolic dysfunctions. CELL DEATH DIFFER. 2022 Nov;:1-13Read more>>
  • Jian Yu. et al. Selective PPAR modulator Diosmin improves insulin sensitivity and promotes browning of white fat. J BIOL CHEM. 2023 Feb;:103059Read more>>
  • Maiara Ferreira Terra. et al. Obesity-Linked PPARγ Ser273 Phosphorylation Promotes Beneficial Effects on the Liver, despite Reduced Insulin Sensitivity in Mice. BIOMOLECULES. 2023 Apr;13(4):632Read more>>
  • Yukiko Yamashita. et al. Discovery of FXR/PPAR Dual Partial Agonist. BIOORGAN MED CHEM. 2023 Mar;:117238Read more>>
  • Zhang Yudian. et al. 3-Hydroxybutyrate ameliorates insulin resistance by inhibiting PPAR Ser273 phosphorylation in type 2 diabetic mice. SIGNAL TRANSDUCT TAR. 2023 May;8(1):1-1Read more>>
  • Jingwen Liu. et al. Bavachinin selectively modulates PPAR and maintains bone homeostasis in Type 2 Diabetes. PHYTOTHER RES. 2023 JuRead more>>
  • Shun Watanabe. et al. Genistein enhances NAD+ biosynthesis by upregulating nicotinamide phosphoribosyltransferase in adipocytes. J NUTR BIOCHEM. 2023 Aug;:109433Read more>>
  • Alpana Mukhuty. et al. Nrf2 inhibition regulates intracellular lipid accumulation in mouse insulinoma cells and improves insulin secretory function. MOL CELL ENDOCRINOL. 2024 Feb;581:112112Read more>>
  • Lei Ma. et al. Structure-based screening, optimization and biological evaluation of novel chrysin-based derivatives as selective PPAR modulators for the treatment of T2DM and hepatic steatosis. EUR J MED CHEM. 2024 Oct;276:116728Read more>>
  • Zuo Shiman. et al. Lipid synthesis, triggered by PPAR T166 dephosphorylation, sustains reparative function of macrophages during tissue repair. NAT COMMUN. 2024 Aug;15(1):1-18Read more>>
VALIDATION IMAGES

Lane 1: HepG2 Cell lysates; Probed with PPAR Gamma (Ser273) Polyclonal Antibody, unconjugated (bs-4888R) at 1:300 overnight at 4°C followed by a conjugated secondary antibody for 60 minutes at 37°C.


Paraformaldehyde-fixed, paraffin embedded Human lung carcinoma; Antigen retrieval by boiling in sodium citrate buffer(pH6) for 15 minutes; Block endogenous peroxidase by 3% hydrogen peroxide for 30 minutes; Blocking buffer (normal goat serum) at 37°C for 20 minutes; Antibody incubation with PPAR Gamma(ser273) Polyclonal Antibody, Unconjugated (bs-4888R) at 1:200 overnight at 4°C, followed by a conjugated secondary antibody and DAB staining.


Paraformaldehyde-fixed, paraffin embedded Human gastric carcinoma; Antigen retrieval by boiling in sodium citrate buffer(pH6) for 15 minutes; Block endogenous peroxidase by 3% hydrogen peroxide for 30 minutes; Blocking buffer (normal goat serum) at 37°C for 20 minutes; Antibody incubation with PPAR Gamma(ser273) Polyclonal Antibody, Unconjugated (bs-4888R) at 1:200 overnight at 4°C, followed by a conjugated secondary antibody and DAB staining.


Lane 1: Mouse Placenta lysates; Probed with PPAR Gamma (Ser273) Polyclonal Antibody, unconjugated (bs-4888R) at 1:300 overnight at 4°C followed by a conjugated secondary antibody for 60 minutes at 37°C.


Lane 1: A549 Cell lysates; Probed with PPAR Gamma (Ser273) Polyclonal Antibody, unconjugated (bs-4888R) at 1:300 overnight at 4°C followed by a conjugated secondary antibody for 60 minutes at 37°C.


An ELISA was performed using a serial dilution of PPAR Gamma (ser273) Polyclonal Antibody (bs-4888R) in antigen-coated wells. The antigen used was a peptide containing the phosphosite of interest. The plot shows the absorbance against the antibody dilution for phosphopeptide antigen and non-phosphorylated peptide antigen.


Lane 1: Human A431 cell lysates; Lane 2: Mouse Adipocyte lysates; Lane 3: Mouse Lung lysates probed with PPAR Gamma Polyclonal Antibody, Unconjugated (bs-4888R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.